Suparna Visits 1 - 2: Cardiovascular Disease Risk Assessment and Management of a Woman with Metabolic Syndrome


Suparna Visits 1 - 2: Cardiovascular Disease Risk Assessment and Management of a Woman with Metabolic Syndrome

Topic: Cardiology
Relevant Terms: Lipidology
Primary Audience: Lipidologists; Cardiologists; Endocrinologists; Internists; Educators; Registered Nurses; Nurse Practitioners; Registered Dietitians; Pharmacists; and other healthcare professionals.
Launch Date: 19-Dec-12
Credits: AMA PRA Category 1 Credit
1 ACPE contact hour
1 ANCC contact hour
1 CDR continuing professional education unit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: HDL MASTER CLASS MAY 2012

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Describe the scope of residual risk in patients with cardiovascular disease.
  2. For Registered Nurses and Nurse Practitioners Only: Provide appropriate care and counsel for patients and their families


    Benjamin J. Ansell, MD, FNLA
    David Geffen School of Medicine
    University of California, Los Angeles
    Los Angeles, CA
    Robert S. Rosenson, MD, FACC, FAHA, FACP, FNLA
    Professor of Medicine
    Mount Sinai School of Medicine
    Cardiometabolic Disorders
    Mount Sinai Heart
    New York, NY
    Estimated Time to Complete Activity
    1 Hour

    Criteria for Success
    Statements of credit will be awarded based on the participant's successful completion of the post-test with a score of 30% or better and the activity evaluation form. If you have questions about this CME/CE activity, please contact the NLA at Please claim credit by December 18, 2013. For Pharmacists, transcript information will be available at within 4 weeks.
    Commercial Support
    This activity is supported by an unrestricted educational grant from Genentech, USA, Merck & Co., Inc., and Abbott Laboratories.
    Credit Designation
           CME credit provided by the National Lipid Association
    The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Lipid Association designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
    Physician Assistants
    NCCPA accepts AMA PRA Category I Credit™ from organizations accredited by ACCME.
       CE Credit provided by Postgraduate Institute for Medicine

    Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    Universal Activity Number – 0809-9999-12-250-H01-P (Application)
    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
    This educational activity for 1.0 contact hour is provided by Postgraduate Institute for Medicine.
    Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
    This program has been approved by the Commission on Dietetic Registration for 1.0 CPEUs. Contact Postgraduate Institute for Medicine ( for details.
    Ansell, Benjamin
    Advisory Board
    Bristol-Myers Squibb; Pfizer, Inc.
    Ownership Interest
    Bruin Pharma
    Rosenson, Robert
    Advisory Board
    Abbott Laboratories; Amgen; AstraZeneca; Genentech; Grain Foods Foundation; LipoScience, Inc.; Sanofi-Aventis
    Contracted Research
    Amgen; Genentech; Roche
    Ownership Interest
    LipoScience, Inc.
    Nothing to Disclose
    PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
    Disclosure of Unlabeled Use and Investigational Product
    This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    Disclosure Declaration
    It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.
    This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.
    System Requirements
    To view this educational activity you will need one of the following web browsers: Google Chrome for Windows, Mac, or Linux; Internet Explorer 7.0+ for Windows; Mozilla 1.4+ for Windows, Mac, or Linux; Firefox 3.5+ for Windows, Mac, or Linux; or Safari 4.0+ for Mac.